Journal ArticleDOI
Complications of Subspecialty Ophthalmic Care: Endophthalmitis after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Medications
Reads0
Chats0
TLDR
The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.Abstract:
The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.read more
Citations
More filters
Journal Article
Petaloid Macular Edema and Outcomes in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Neepa Shah,Maureen G. Maguire,Daniel F. Martin,James Shaffer,Gui-Shuang Ying,Juan E. Grunwald,Cynthia A. Toth,Glenn J. Jaffe,Ebenezer Daniel +8 more
Journal ArticleDOI
Intravitreal Injection--Technique and Safety.
TL;DR: The IVT injection practice protocol is described and compared with the most recent international guidelines and a summary table that shows the clinical features of true, sterile, and pseudoendophthalmitis is presented.
Journal ArticleDOI
LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Florentina J. Freiberg,Troels Brynskov,Marion R. Munk,Torben Lykke Sørensen,Sebastian Wolf,Magdalena A. Wirth,Matthias Becker,Stephan Michels +7 more
TL;DR: The standardized sterile technique in an operation room with laminar airflow showed very low rates of endophthalmitis at three European sites.
Journal ArticleDOI
High Glucose-induced Retinal Pericyte Apoptosis Depends on Association of GAPDH and Siah1
TL;DR: It is demonstrated that dissociation of the GAPDH/Siah1 pro-apoptotic complex can block high glucose-induced pericyte apoptosis, widely considered a hallmark feature of DR.
References
More filters
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Journal ArticleDOI
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F. Martin,Maureen G. Maguire,Stuart L. Fine,Gui-Shuang Ying,Glenn J. Jaffe,Juan E. Grunwald,Cynthia A. Toth,Maryann Redford,Frederick L. Ferris +8 more
TL;DR: Ranibizumab and bevacizumAB had similar effects on visual acuity over a 2-year period and switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2.
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
David M. Brown,Quan Dong Nguyen,Dennis M. Marcus,David S. Boyer,Sunil S. Patel,Leonard Feiner,Patricio G. Schlottmann,Amy Chen Rundle,Jiameng Zhang,Roman G. Rubio,Anthony P. Adamis,Jason S. Ehrlich,J Jill Hopkins +12 more
TL;DR: The strong VA gains and improvement in retinal anatomy achieved with ranibizumab at month 24 were sustained through month 36, and the incidence of serious adverse events potentially related to systemic vascular endothelial growth factor inhibition remained low over time.
Journal ArticleDOI
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
TL;DR: An overview of safety data for intravitreal injection of common anti-VEGF agents is provided and encouraging results in halting the disease and improving the vision are provided.
Related Papers (5)
Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications
Luis J. Haddock,Justin Yamanuha +1 more